Clinical trials
PET/CT clinical trials
Below are recruiting pet/ct clinical trials, each written for real people, not researchers. We’re tracking 362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT06411678RecruitingEarly Phase 1
Testing a new scan for breast cancer before treatment
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
Dongcheng, Beijing MunicipalityAges 18–70 - NCT06413355RecruitingPhase 1
FAPI-74 PET scan for adults with fibrosis
This study tests a new type of PET/CT scan (FAPI-74) to see if it can detect areas of scarring (fibrosis) in the body. It may help doctors better understand and monitor conditions like certain cancers, infections after transplants, and heart inflammation.
Philadelphia, PennsylvaniaAges 21 years+ - NCT06414902RecruitingPhase 1
PET scan to see if chemoradiation is working for esophageal cancer
This trial uses a special PET/CT scan to see how well your esophageal cancer responds to chemotherapy and radiation. It helps doctors find out if the treatment is working early on.
Houston, TexasAges 18 years+ - NCT06438250RecruitingEarly Phase 1
Studying a new imaging agent for solid tumors
This trial tests a new imaging agent called 68Ga-JH04 that is used with a PET/CT scan. The goal is to see how the agent travels through the body and how much radiation it gives off, which may help doctors better understand and treat your tumor.
Fuzhou, FujianAges 18 years+ - NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06450548Recruiting
PSMA and FDG PET scans before 177Lu-PSMA therapy
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
RouenAges 18 years+ - NCT06451536Recruiting
Special PET Scan Before Immunotherapy for Mesothelioma
This trial uses a special PET scan (called Ga-68 FAPI) to see if it can help doctors better plan or monitor immunotherapy for people with pleural mesothelioma. It may help doctors predict how well the treatment will work.
AnkaraAges 18 years+ - NCT06455358RecruitingPhase 1/Phase 2
A new PET scan to find neuroendocrine tumors
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Basel, Canton of Basel-CityAges 18 years+ - NCT06455761RecruitingEarly Phase 1
PET scan with a new tracer for solid tumors
This trial uses a special PET scan (68Ga-DOTA-NI-FAPI04) to get clearer images of various solid tumors. It may help doctors see your cancer better and plan your treatment.
FuzhouAges 18–80 - NCT06500065Recruiting
Testing a new PET scan for soft tissue sarcoma
This study uses a special PET/CT scan (68Ga-DOTATATE) to see if it can better find soft tissue sarcomas. You will also have a standard PET/CT scan for comparison, and the results may help guide your treatment.
Columbus, OhioAges 18 years+ - NCT06520319RecruitingPhase 1
Comparing two PET tracers for recurrent MTC
This study compares a new imaging agent called 68Ga-MGS5 with the standard agent 68Ga-DOTATATE to see which one better detects recurrent medullary thyroid carcinoma on a PET/CT scan. The goal is to improve tumor detection in people whose MTC has returned.
Fuzhou, FujianAges 18–80 - NCT06557590Recruiting
PET scan with FAPI tracer for cancer imaging
This study uses a special PET scan called 18F-FAPI-04 to take detailed images of different kinds of cancer. It aims to see if this scan can help doctors better find and monitor tumors.
Changsha, HunanAges 18–90 - NCT06597526Recruiting
PET/CT scanning to guide treatment for stomach cancer with abdominal spread
This trial uses two types of PET/CT scans (FDG and FAPI) to see how well chemotherapy or other treatments work before surgery for stomach cancer that has spread to the lining of the abdomen. The goal is to find the best way to measure treatment response and help guide your care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT07690306Enrolling by invitation
AI study to improve prostate cancer diagnosis with MRI and PSMA PET scans
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06612580RecruitingEarly Phase 1
New PET scan agent for prostate cancer
This study tests a new imaging agent called 68Ga-AAZTA-NI-093 for a special PET/CT scan that might help see prostate cancer more clearly. It is for people with prostate cancer, whether they've had treatment or not.
Fuzhou, FujianAges 18–80 - NCT06618872Recruiting
Comparing tau and amyloid PET scans for memory problems
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
Geneva, Canton of GenevaAges 50–85 - NCT06629207Recruiting
AI predicts Parkinson's risk in sleep behavior disorder
This study uses artificial intelligence to analyze brain scans and predict whether people with REM sleep behavior disorder are at risk of developing Parkinson's disease. It aims to find early signs before symptoms appear.
BernAges 18 years+ - NCT06636175RecruitingEarly Phase 1
New imaging test for blood cancers
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
St Louis, MissouriAges 18 years+ - NCT06645808RecruitingEarly Phase 1
PET imaging study for various solid tumors
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Groningen, Provincie GroningenAges 18 years+ - NCT06648317Recruiting
New PET scan for lung tumors using a Nectin-4 probe
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06659276Recruiting
Comparing two imaging methods for multiple myeloma
This trial compares two whole-body imaging scans (full-body MRI using DWI and a PET/CT scan) to see which does a better job detecting and staging active multiple myeloma. If you have been newly diagnosed or are being evaluated for suspected symptomatic myeloma, joining could help doctors learn which test is best for planning your care.
BolognaAges 18 years+
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pet/ct?
- Yes. Clin2 currently lists 362 recruiting pet/ct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pet/ct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pet/ct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.